The molecular and cellular mechanisms associated with the destruction of terminal bronchioles in COPD
- PMID: 34675046
- DOI: 10.1183/13993003.01411-2021
The molecular and cellular mechanisms associated with the destruction of terminal bronchioles in COPD
Abstract
Rationale: Peripheral airway obstruction is a key feature of chronic obstructive pulmonary disease (COPD), but the mechanisms of airway loss are unknown. This study aims to identify the molecular and cellular mechanisms associated with peripheral airway obstruction in COPD.
Methods: Ten explanted lung specimens donated by patients with very severe COPD treated by lung transplantation and five unused donor control lungs were sampled using systematic uniform random sampling (SURS), resulting in 240 samples. These samples were further examined by micro-computed tomography (CT), quantitative histology and gene expression profiling.
Results: Micro-CT analysis showed that the loss of terminal bronchioles in COPD occurs in regions of microscopic emphysematous destruction with an average airspace size of ≥500 and <1000 µm, which we have termed a "hot spot". Based on microarray gene expression profiling, the hot spot was associated with an 11-gene signature, with upregulation of pro-inflammatory genes and downregulation of inhibitory immune checkpoint genes, indicating immune response activation. Results from both quantitative histology and the bioinformatics computational tool CIBERSORT, which predicts the percentage of immune cells in tissues from transcriptomic data, showed that the hot spot regions were associated with increased infiltration of CD4 and CD8 T-cell and B-cell lymphocytes.
Interpretation: The reduction in terminal bronchioles observed in lungs from patients with COPD occurs in a hot spot of microscopic emphysema, where there is upregulation of IFNG signalling, co-stimulatory immune checkpoint genes and genes related to the inflammasome pathway, and increased infiltration of immune cells. These could be potential targets for therapeutic interventions in COPD.
Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org.
Conflict of interest statement
Conflict of interest: F. Xu has nothing to disclose. Conflict of interest: D.M. Vasilescu has nothing to disclose. Conflict of interest: D. Kinose has nothing to disclose. Conflict of interest: N. Tanabe has nothing to disclose. Conflict of interest: K.W. Ng has nothing to disclose. Conflict of interest: H.O. Coxson has nothing to disclose. Conflict of interest: J.D. Cooper has nothing to disclose. Conflict of interest: T-L. Hackett has nothing to disclose. Conflict of interest: S.E. Verleden has nothing to disclose. Conflict of interest: B.M. Vanaudenaerde has nothing to disclose. Conflict of interest: C.S. Stevenson reports other (salary) from Johnson and Johnson, outside the submitted work. Conflict of interest: M.E. Lenburg reports grants from Genentech, during the conduct of the study and other (stock) from Metera Pharmaceuticals, outside the submitted work. Conflict of interest: A. Spira is an employee of Johnson and Johnson. Conflict of interest: W.C. Tan reports personal fees for advisory board work from GlaxoSmithKline, Canada, and AstraZenenca, Canada, outside the submitted work. Conflict of interest: D.D. Sin reports grants and personal fees for lectures from AstraZeneca and personal fees for lectures from Boehringer Ingelheim, outside the submitted work. Conflict of interest: R.T. Ng has nothing to disclose. Conflict of interest: J.C. Hogg reports grants from Genentech, Johnson and Johnson Corporation, Canadian Institute of Health Research, US National Institutes of Health, Katholieke Universiteit Leuven, Parker B Francis Foundation, St Paul's Hospital Foundation, BCLUNG Association and BC Heart and Stroke Foundation, during the conduct of the study.
Comment in
-
Quality over quantity: the importance of collecting relevant samples to understand complex diseases.Eur Respir J. 2022 May 26;59(5):2200418. doi: 10.1183/13993003.00418-2022. Print 2022 May. Eur Respir J. 2022. PMID: 35618280 No abstract available.
-
Broadening concepts of core pathobiology in various aspects of COPD development.Eur Respir J. 2022 Dec 8;60(6):2201531. doi: 10.1183/13993003.01531-2022. Print 2022 Dec. Eur Respir J. 2022. PMID: 36202414 No abstract available.
-
Reply to: Broadening concepts of core pathobiology in various aspects of COPD development.Eur Respir J. 2022 Dec 8;60(6):2201796. doi: 10.1183/13993003.01796-2022. Print 2022 Dec. Eur Respir J. 2022. PMID: 36202415 No abstract available.
Similar articles
-
Small-airway obstruction and emphysema in chronic obstructive pulmonary disease.N Engl J Med. 2011 Oct 27;365(17):1567-75. doi: 10.1056/NEJMoa1106955. N Engl J Med. 2011. PMID: 22029978 Free PMC article.
-
Analysis of airway pathology in COPD using a combination of computed tomography, micro-computed tomography and histology.Eur Respir J. 2018 Feb 14;51(2):1701245. doi: 10.1183/13993003.01245-2017. Print 2018 Feb. Eur Respir J. 2018. PMID: 29444912 Free PMC article.
-
The cellular and molecular determinants of emphysematous destruction in COPD.Sci Rep. 2017 Aug 25;7(1):9562. doi: 10.1038/s41598-017-10126-2. Sci Rep. 2017. PMID: 28842670 Free PMC article.
-
Recent advances in airway imaging using micro-computed tomography and computed tomography for chronic obstructive pulmonary disease.Korean J Intern Med. 2021 Nov;36(6):1294-1304. doi: 10.3904/kjim.2021.124. Epub 2021 Oct 6. Korean J Intern Med. 2021. PMID: 34607419 Free PMC article. Review.
-
Small airway obstruction in COPD: new insights based on micro-CT imaging and MRI imaging.Chest. 2013 May;143(5):1436-1443. doi: 10.1378/chest.12-1766. Chest. 2013. PMID: 23648907 Free PMC article. Review.
Cited by
-
Mucosal immune alterations at the early onset of tissue destruction in chronic obstructive pulmonary disease.Front Immunol. 2023 Oct 17;14:1275845. doi: 10.3389/fimmu.2023.1275845. eCollection 2023. Front Immunol. 2023. PMID: 37915582 Free PMC article.
-
A model of dysregulated crosstalk between dendritic, natural killer, and regulatory T cells in chronic obstructive pulmonary disease.Trends Immunol. 2024 Jun;45(6):428-441. doi: 10.1016/j.it.2024.04.010. Epub 2024 May 18. Trends Immunol. 2024. PMID: 38763820 Free PMC article.
-
Understanding COPD Etiology, Pathophysiology, and Definition.Respir Care. 2023 Jul;68(7):859-870. doi: 10.4187/respcare.10873. Respir Care. 2023. PMID: 37353333 Free PMC article.
-
Taking Small Airways in Chronic Obstructive Pulmonary Disease to TASC.Am J Respir Crit Care Med. 2023 May 1;207(9):1114-1115. doi: 10.1164/rccm.202302-0295ED. Am J Respir Crit Care Med. 2023. PMID: 36821491 Free PMC article. No abstract available.
-
Screening COPD-Related Biomarkers and Traditional Chinese Medicine Prediction Based on Bioinformatics and Machine Learning.Int J Chron Obstruct Pulmon Dis. 2024 Sep 24;19:2073-2095. doi: 10.2147/COPD.S476808. eCollection 2024. Int J Chron Obstruct Pulmon Dis. 2024. PMID: 39346628 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials